Pay in 4 interest-free payments of $7.02 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Current status: TRIUMPH-4 results available: December 2025 readout showing 28.7% weight loss at 68 weeks (Giblin et al., PMID 41090431) Additional TRIUMPH trials: Expected to report results through 2026, including TRIUMPH-Outcomes (cardiovascular endpoints, NCT06383390, completion Feb 2029) NDA submission timing: Eli Lilly must compile the full trial package before submitting
That is remarkably compact
Tirzepatide Tirzepatide (LY3298176) is a synthetic dual agonist at the GIP and GLP-1 receptors, supplied as a pre-loaded multi-dose injector pen for research and laboratory use only
Fat-burning and metabolism support tends to build gradually, especially when paired with consistent nutrition and movement
These dates are backed by extensive stability studies conducted by Novo Nordisk, the manufacturer
It is described as a triple hormone receptor agonist, meaning it activates: GLP-1 receptors GIP receptors Glucagon receptors This differentiates it from currently approved therapies such as: Wegovy (GLP-1 only) Mounjaro (GLP-1 + GIP) Retatrutide adds glucagon receptor activation, creating a triple-pathway metabolic effect
US$ 24.44
US$ 29.93
US$ 22.81
US$ 23.07
US$ 23.33
